These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 20092990)

  • 1. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
    Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
    Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
    Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S
    Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
    Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
    Michaelson MD; Ryan DP; Fuchs CS; Supko JG; Garcia-Carbonero R; Paul Eder J; Clark JW
    Cancer; 2003 Jan; 97(1):148-54. PubMed ID: 12491516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
    Infante JR; Jones SF; Bendell JC; Greco FA; Yardley DA; Lane CM; Spigel DR; Hainsworth JD; Burris HA
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):137-44. PubMed ID: 21626051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
    Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.
    Saif MW; Li J; Lamb L; Kaley K; Elligers K; Jiang Z; Bussom S; Liu SH; Cheng YC
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):373-80. PubMed ID: 24297682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer].
    Jin J; Li YX; Liu YP; Wang WH; Li T; Li N; Song YW
    Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):393-6. PubMed ID: 17045010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
    Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
    Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
    Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
    Saif MW; Sarantopoulos J; Patnaik A; Tolcher AW; Takimoto C; Beeram M
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1565-73. PubMed ID: 21547572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Trarbach T; Reinacher-Schick A; Hegewisch-Becker S; Vanhoefer U; Frieling T; Lehnert L; Schmiegel W; Graeven U
    Onkologie; 2010; 33(3):89-93. PubMed ID: 20215798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer.
    Ohno S; Mitsuyama S; Tamura K; Nishimura R; Tanaka M; Hamada Y; Kuroki S;
    Anticancer Res; 2007; 27(2):1009-13. PubMed ID: 17465235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
    Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
    Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.